Compare ORIO & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ORIO | TVGN |
|---|---|---|
| Founded | N/A | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 21.3M |
| IPO Year | 2014 | 2021 |
| Metric | ORIO | TVGN |
|---|---|---|
| Price | $0.98 | $7.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 83.2K | 4.1K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.52 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.14 |
| 52 Week High | $1.40 | $12.03 |
| Indicator | ORIO | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 62.41 |
| Support Level | $0.82 | $6.41 |
| Resistance Level | $1.12 | $7.42 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 56.58 | 100.00 |
Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.